曲妥珠单抗治疗八个周期后出现曲妥珠单抗诱导的血小板减少症。
Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment.
作者信息
Zhou Qiong, Dong Jie, Jiang Xiaodong, Pan Yueyin, Han Xinghua
机构信息
Department of Oncology, Provincial Hospital affiliated to Anhui Medical University, Hefei, Anhui Province, 230032, China.
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province, 230001, China.
出版信息
Open Med (Wars). 2020 Jul 13;15(1):659-662. doi: 10.1515/med-2020-0201. eCollection 2020.
Trastuzumab, a humanized monoclonal antibody derived from recombinant DNA, is used in patients with breast cancer with HER2 gene amplification. The survival benefit from trastuzumab has been well established in patients with early and metastatic breast cancer who had over expression of HER2. We reported a case of severe thrombocytopenia after eight cycles of trastuzumab treatment for breast cancer. Before the 9th trastuzumab treatment, the patient's platelet decreased to 48 × 10/L. Recombinant human thrombopoietin was used, and the platelet level increased to normal level. Before the 10th treatment, the platelet count of the patient was 99 × 10/L. However, during the 10th and 11th trastuzumab treatment, the platelet count decreased to 5 × 10/L in 24 h. After treatment with TPO and corticosteroids, the platelet levels increased to the normal level in 7 days. Trastuzumab-induced thrombocytopenia is rare but still occurred even after 8 cycles of trastuzumab treatment.
曲妥珠单抗是一种源自重组DNA的人源化单克隆抗体，用于治疗HER2基因扩增的乳腺癌患者。曲妥珠单抗对HER2过表达的早期和转移性乳腺癌患者的生存益处已得到充分证实。我们报告了1例乳腺癌患者在接受8个周期曲妥珠单抗治疗后出现严重血小板减少的病例。在第9次曲妥珠单抗治疗前，患者血小板降至48×10/L。使用重组人血小板生成素后，血小板水平升至正常。第10次治疗前，患者血小板计数为99×10/L。然而，在第10次和第11次曲妥珠单抗治疗期间，血小板计数在24小时内降至5×10/L。经血小板生成素和糖皮质激素治疗后，血小板水平在7天内升至正常。曲妥珠单抗诱导的血小板减少虽罕见，但即使在8个周期曲妥珠单抗治疗后仍会发生。
Zotero 插件